This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good afternoon and thank you for standing by. Welcome to Kean Biotech's fourth quarter and full year 2023 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be open to questions. If you have a question, please press star 1 1 on your touchtone phone. If you'd like to withdraw your question, please press star 1 1 again. This conference is being recorded today, March 26, 2024. I would like to turn the conference call over to Ray Dupuy, Kean Biotech's Chief Financial Officer. Please go ahead.
spk00: Thank you, operator. Good afternoon and welcome everyone to Kean Biotech's fourth quarter and full year 2023 earnings conference call. We are delighted to have you join us today. This call will cover Kean's financial and operating results, along with a discussion of some of our recent highlights and goals for 2024 and beyond. Following our prepared remarks, We will open the conference call to a question and answer session. Our call today will be led by King's Chief Executive Officer Mark Edwards. Before we begin our formal remarks. I would like to remind everyone that some of the statements on this conference call contains certain forward looking information and statements within the meaning of securities law, which may not be based on historical fact,
Disclaimer